TCRT icon

Alaunos Therapeutics

1.43 USD
-0.05
3.38%
At close Mar 14, 4:00 PM EDT
1 day
-3.38%
5 days
-11.73%
1 month
-11.73%
3 months
-12.80%
6 months
-33.49%
Year to date
-27.41%
1 year
-91.28%
5 years
-99.50%
10 years
-99.93%
 

About: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Employees: 34

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 29 [Q3] → 30 (+1) [Q4]

7.5% less ownership

Funds ownership: 12.0% [Q3] → 4.51% (-7.5%) [Q4]

78% less capital invested

Capital invested by funds: $623K [Q3] → $138K (-$485K) [Q4]

83% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 12

Research analyst outlook

We haven’t received any recent analyst ratings for TCRT.

Financial journalist opinion

Charts implemented using Lightweight Charts™